ChromaDex Co. (NASDAQ:CDXC) Sees Large Increase in Short Interest

ChromaDex Co. (NASDAQ:CDXC) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 31st total of 1,940,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 1.6 days. Approximately 4.3% of the shares of the company are short sold.

ChromaDex Price Performance

CDXC stock traded down $0.14 during trading hours on Monday, reaching $5.49. The stock had a trading volume of 342,099 shares, compared to its average volume of 347,043. ChromaDex has a fifty-two week low of $1.46 and a fifty-two week high of $7.97. The stock has a market capitalization of $419.33 million, a PE ratio of 549.55 and a beta of 2.21. The stock has a 50-day simple moving average of $6.07 and a 200 day simple moving average of $4.69.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the previous year, the company posted ($0.01) EPS. On average, sell-side analysts forecast that ChromaDex will post 0.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 15th. Roth Mkm increased their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th.

Insider Buying and Selling at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 9.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CDXC. BSW Wealth Partners bought a new stake in shares of ChromaDex during the 3rd quarter valued at about $324,000. BNP Paribas Financial Markets raised its stake in shares of ChromaDex by 1,885.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after purchasing an additional 69,582 shares during the period. State Street Corp lifted its holdings in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after buying an additional 62,692 shares in the last quarter. Barclays PLC grew its position in shares of ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after purchasing an additional 53,472 shares in the last quarter. Finally, Sargent Investment Group LLC purchased a new stake in shares of ChromaDex in the 4th quarter valued at about $263,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.